Pilsicainide
 | |
| Clinical data | |
|---|---|
| AHFS/Drugs.com | International Drug Names |
| Routes of administration | Oral, IV |
| ATC code | none |
| Identifiers | |
| |
| CAS Number |
88069-67-4  |
| PubChem (CID) | 4820 |
| ChemSpider |
4654  |
| UNII |
AV0X7V6CSE |
| KEGG |
D08377 |
| ChEMBL |
CHEMBL163238 |
| Chemical and physical data | |
| Formula | C17H24N2O |
| Molar mass | 272.38 g/mol |
| 3D model (Jmol) | Interactive image |
| |
| |
| (what is this?) (verify) | |
Pilsicainide (INN) is an antiarrhythmic agent. It is marketed in Japan as サンリズム (Sunrythm). The JAN applies to the hydrochloride salt, pilsicainide hydrochloride.
Pilsicainide is a drug used clinically in Japan to treat cardiac arrhythmias. It functions by blocking the fast inward movement of sodium ions through the Nav1.5 sodium channel[1] that contributes to the rapid depolarization characteristic of phase 0 in the cardiac action potential. Pilsicainide is a pure sodium channel blocker, meaning it does not significantly affect any other cardiac channels including potassium and calcium channels.[2] Pilsicainide binds to a common site on the sodium channel through either intracellular or extracellular application(3). The affinity of pilsicainide for the sodium channel receptor and its rate of binding are dependent on the state of the channel. It has been proven to have a greater affinity for the receptor in its inactivated state as opposed to resting or open(4), thereby following the modulated receptor hypothesis(5). Binding of pilsicainide selectively inhibits the channel(6), preventing the movement of sodium ions into the cardiac cell. This decreases the rate of depolarization of the cell membrane as well as the action potential amplitude, but has no effect on the overall duration of the action potential(6). Suppression of the depolarization rate is use-dependent(7), and therefore inhibition increases with increased stimulation. Pilsicainide also causes delayed impulse conduction through the myocardium in a dose-dependent manner(8). The effects of pilsicainide have a slow rate of onset and offset resulting in a prolonged recovery time(9). This contributes to its potent blocking activity and its classification as a class 1c antiarrhythmic agent(10). A cardiac arrhythmia includes any abnormal heartbeat and can be manifested as tachycardia, bradycardia, or other irregular rhythms. Pilsicainide has been proven successful in treating both ventricular(11) and supraventricular arrhythmias with few adverse effects(12). It is especially effective in the treatment of atrial fibrillation.[3] Atrial fibrillation is the most common type of arrhythmia(14). It may result from various heart abnormalities or may occur spontaneously in a seemingly healthy individual(15). Atrial fibrillation is characterized by rapid, disorganized electrical impulses in the atria resulting in depolarization of only a small group of myocardial cells. This prevents the atria from undergoing coordinated contraction, instead resulting in small fibrillations of the heart muscle. Re-entry occurs when an impulse does not die after activating the heart but instead returns to the atria and causes re-excitation(16). Simultaneous re-entry of multiple impulses with short wavelengths results in atrial fibrillation(17). Impulse wavelength is the product of the conduction velocity and the effective refractory period. Pilsicainide suppresses atrial conduction velocity but also increases the effective refractory period(18). Its effects on the refractory period are significantly more substantial, and therefore pilsicainide treatment results in an increased wavelength and termination of atrial fibrillation.[4] A single oral dose of pilsicainide effectively restores normal sinus rhythm in patients with recent-onset atrial fibrillation and a healthy left ventricle.[5] Long-term therapy with pilsicainide is successful in treating chronic atrial fibrillation).[6]
3. Hattori Y, and Inomata N. Modes of the Na channel blocking action of pilsicainide, a new antiarrhythmic agent, in cardiac cells. Jpn J Pharmacol. 1992;58(4):365-73.
4. Desaphy JF, Dipalma A, Costanza T, Bruno C, Lentini G, Franchini C, George A, and Conte Camerino D. Molecular determinants of state-dependent block of voltage-gated sodium channels by pilsicainide. Br J Pharmacol. 2010;160(6):1521-33.
5. Hille B. Local anesthetics: hydrophilic and hydrophobic pathways for the drug-receptor reaction. J Gen Physiol. 1977;69:497-515.
6. Hattori Y, Inomata N, Aisaka K, Ishihara T. Electrophysiological actions of N-(2,6-dimethylphenyl)-8-pyrrolizidine-acetamide hydrochloride hemihydrate (SUN 1165), a new antiarrhythmic agent. J Cardiovasc Pharmacol. 1986;8(5):998-1002.
7. Courtney KR. Interval-dependent effects of small antiarrhythmic drugs on excitability of guinea-pig myocardium. J Mol Cell Cardiol. 1980;12(11):1273-86.
8. Hidaka T, Hamasaki S, Aisaka K, Ishihara T, Morita M, Toyama J, and Yamada K. N-(2,6-dimethylphenyl)-8-pyrrolizidineacetamide hydrochloride hemihydrate (SUN 1165), a new antiarrhythmic agent: effects on cardiac conduction. Arzneimittelforschung. 1985;35(9):1381-6.
9. Hattori Y, Hidaka T, Aisaka K, Satoh F, and Ishihara T. Effect of SUN 1165, a new potent antiarrhythmic agent, on the kinetics of rate-dependent block of Na channels and ventricular conduction of extrasystoles. J Cardiovasc Pharmacol. 1988;11(4):407-12.
10. Campbell TJ. Kinetics of onset of rate-dependent effects of class I antiarrhythmic drugs are important in determining their effects on refractoriness in guinea-pig ventricle, and provide a theoretical basis for their subclassification. Cardiovasc Res. 1983;17(6):344-52.
11. Hashimoto H, Satoh N, and Nakashima M. Effects of SUN-1165, N-(2,6-dimethylphenyl)-8-pyrrolizidine acetamide hydrochloride hemihydrate, a new class I antiarrhythmic drug, on ventricular arrhythmias, intraventricular conduction, and the refractory period in canine myocardial infarction. J Cardiovasc Pharmacol. 1992;19(3):417-24.
12. Ino T, Atarashi H, Kuruma A, Onodera T, Saitoh H, and Hayakawa H. Electrophysiologic and hemodynamic effects of a single oral dose of pilsicainide hydrochloride, a new class 1c antiarrhythmic agent. J Cardiovasc Pharmacol. 1998;31(1):157-64.
14. Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, and Hart RG. Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med. 1995;155(5):469-73.
15. Dang D, Arimie R, and Haywood LJ. A review of atrial fibrillation. J Natl Med Assoc. 2002;94(12):1036-48.
16. Veenhuyzen GD, Simpson CS, and Abdollah H. Atrial Fibrillation. Can Med Assoc J. 2004;171(7):755-60.
17. Rensma PL, Allessie MA, Lammers WJ, Bonke FI, and Schalij MJ. Length of excitation wave and susceptibility to reentrant atrial arrhythmias in normal conscious dogs. Circ Res. 1988;62(2):395-410.
18. Kanki H, Mitamura H, Takatsuki S, Sueyoshi K, Shinagawa K, Sato T, and Ogawa S. Postrepolarization refractoriness as a potential anti-atrial fibrillation mechanism of pilsicainide, a pure sodium channel blocker with slow recovery kinetics. Cardiovasc Drugs Ther. 1998;12(5):475-82.
References
- ↑ Inomata N, Ishihara T, and Akaike N. SUN 1165: a new antiarrhythmic Na current blocker in ventricular myocytes of guinea-pig. Comp Biochem Physiol C. 1987;87(2):237-43.
- ↑ Yamashita T, Murakawa Y, Sezaki K, Hayami N, Inoue M, Fukui E, and Omata M. Uniqueness of pilsicainide in class Ic antiarrhythmics. Jpn Heart J. 1998;39(3):389-97.
- ↑ Atarashi H, Inoue H, Hiejima K, and Hayakawa H. Conversion of recent-onset atrial fibrillation by a single oral dose of pilsicainide (pilsicainide suppression trial on atrial fibrillation). Am J Cardiol. 1996;78(6):694-7.
- ↑ Shinagawa K, Mitamura H, Takeshita A, Sato T, Kanki H, Takatsuki S, and Ogawa S. Determination of refractory periods and conduction velocity during atrial fibrillation using atrial capture in dogs: direct assessment of the wavelength and its modulation by a sodium channel blocker, pilsicainide. J Am Coll Cardiol. 2000;35(1):246-53.
- ↑ Atarashi H, Inoue H, Hiejima K, and Hayakawa H. Conversion of recent-onset atrial fibrillation by a single oral dose of pilsicainide (pilsicainide suppression trial on atrial fibrillation). Am J Cardiol. 1996;78(6):694-7.
- ↑ Okishige K, Nishizaki M, Azegami K, Igawa M, Yamawaki N, and Aonuma K. Pilsicainide for conversion and maintenance of sinus rhythm in chronic atrial fibrillation: a placebo-controlled, multicenter study. Am Heart J. 2000;140(3):e13.